Regarding NAM, a new clinical trial (NCT03061474) is investigating whether NAM can reduce the phosphorylation of the tau protein found in cerebrospinal fluid (CSF) in people with mild cognitive impairment or mild AD [113]. Here, MAPT is linked to Alzheimer disease.